Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients

Mojtahed, Saam A; Boyer, Nicole; Rao, Sarojini; Gajewski, Thomas F.; Tseng, Jennifer F.; Turaga, Kiran K.

doi:10.1245/s10434-021-10288-4

Cited by 6 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our model shows that cost-effectiveness mainly depends on drug acquisition costs, which is in line with other Markov models comparing systemic adjuvant therapies (including ipilimumab) from a US ($) perspective. 47,48 Although discrepancies between formal and actual list prices are not uncommon, drug prices seemed to be quite similar in The Netherlands. 49 The actual prices are not freely accessible, however, and are different across countries.…”

Section: Esmo Openmentioning

confidence: 99%

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation

et al. 2021

View full text Add to dashboard Cite

Section: Esmo Openmentioning

confidence: 99%

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation

et al. 2021

View full text Add to dashboard Cite

“…Другим примером подобных затруднений являются клинические испытания адъювантной таргетной терапии. Как и следовало ожидать, использование специфических и эффективных препаратов по отношению к опухолям, имеющим соответствующую молекулярную мишень, многократно увеличивает время до прогрессирования [22][23][24][25][26][27]. Действительно, таргетная терапия, направленная на опухолевые клетки с сенситизирующими мутациями, должна демонстрировать эффект почти в 100% случаев, вне зависимости от того, наблюдаются ли у пациента видимые опухолевые очаги или лишь остаточные опухолевые клетки.…”

Section: уменьшение стоимости лечения при сохранении его клинической ...unclassified

Opportunities for antitumor drugs replacement

Imyanitov¹,

Проценко²,

Семиглазова³

2022

Voprosy Onkologii

View full text Add to dashboard Cite

Выбор оптимальной тактики лекарственного лечения для онкологических пациентов зависит не только от сведений о потенциальной клинической эффективности тех или иных фармакологических субстанций, но и от целого ряда сопутствующих нюансов, в частности, перечня зарегистрированных медицинских показаний, стоимости препаратов и их фактической доступности. В случае невозможности использования общепринятых лекарственных схем возникает необходимость поиска альтернативных, схожих по эффективности способов лечения. В данной работе рассматриваются примеры потенциальной взаимозаменяемости противоопухолевых препаратов, а также обсуждаются возможности уменьшения стоимости терапии без ущерба для её клинической эффективности.

show abstract

“…Melanoma is a malignant tumor caused by abnormal differentiation of melanocytes (1). Melanocytes exist in the neural crest of the embryo and migrate to many parts of the body during fetal development; mainly in the basal epidermis, hair follicles, mucosal surfaces, meninges and the choroidal layers of the eyes (2,3). Melanoma is most common in the skin, but the rectum, eyes, anus and vulva are also frequent sites.…”

Section: Introductionmentioning

confidence: 99%

Plasma Exosome-Derived SENP1 May Be a Potential Prognostic Predictor for Melanoma

Bai

Shi

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo evaluate plasma exosome-derived SUMO-specific protease (SENP)1 levels and assess their prognostic value in melanoma.Patients and MethodsWe extracted exosomes from the plasma of 126 melanoma patients, and identified them with transmission electron microscopy, nanoparticle tracking analysis and western blotting. The plasma exosome-derived SENP1 levels of melanoma patients and healthy controls were detected with ELISA.ResultsPlasma exosome-derived SENP1 levels in melanoma patients were significantly upregulated than in healthy controls (P < 0.001). Plasma exosome-derived SENP1 levels in melanoma patients with tumor size >10 cm, located in the mucosa or viscera, with Clark level IV/V, with lymph node metastasis, and TNM stages IIb–IV were significantly higher than in patients in with tumor size <10 cm, located in the skin, with Clark level I–III, without lymph node metastasis, and TNM stages IIb–IV (all P < 0.05). Disease-free survival (DFS) and overall survival (OS) were worse in melanoma patients who had higher plasma exosome-derived SENP1 levels than lower plasma exosome-derived SENP1 levels (both P < 0.001). Area under the receiver operating characteristic curve (AUROC) of plasma exosome-derived SENP1 for predicting 3-year DFS of melanoma patients was 0.82 [95% confidence interval (CI): 0.74–0.88], with a sensitivity of 81.2% (95% CI: 69.9–89.6%) and specificity of 75.4% (95% CI: 62.2–85.9%). The AUROC of plasma exosome-derived SENP1 for predicting 3-year OS of melanoma patients was 0.76 (95% CI: 0.67–0.83), with a sensitivity of 95.7% (95% CI: 85.5–99.5%) and specificity of 62.0% (95% CI: 50.4–72.7%).ConclusionsMelanoma patients with higher plasma exosome-derived SENP1 levels had worse DFS and OS. The plasma exosome-derived SENP1 levels may be a potential prognostic predictor for 3-year DFS and 3-year OS of melanoma.

show abstract

Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients

Cited by 6 publications

References 26 publications

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation

Opportunities for antitumor drugs replacement

Plasma Exosome-Derived SENP1 May Be a Potential Prognostic Predictor for Melanoma

Contact Info

Product

Resources

About